Abstract
Purpose/Introduction: Osteoporosis is a special common disease in the recent time. There are many limitations in diagnosis and treatments. Patients have lots of adherences barriers and physicians are apprehensive about side effect and drug efficacy. Therefore, we have the research to help patients are more comfortable in treatment and physicians have a effectively drug for osteoporosis patients. Objective: To evaluate the initial effectiveness of zoledronic acid (Aclasta 5mg/100ml) in the osteoporosis patients at the internal medicine department A in Tien Giang central general hospital from 2019 to 2021. Materials and Methods: The case series study of all patients diagnosed anh had a intravenous zoledronic acid in osteoporosis treatment at the internal medicine department A in Tien Giang central general hospital from February 2019 to July 2021. Results: The study of 32 patients who are older than 50 years old, we have: The group of osteoporosis patients are selected for treatment with zoledronic acid has the following characteristics: female 84,4%, older than 80 is 43,8%, agricultural occupation 62,4%, living in rural areas 71,9%, having many comorbidities such as: hypertention 59,4%, Cushing 31,2%, vertebral collapse 15,6%, diabetes type 2 is15,6%, asthma 12,5%, femoral neck fracture 6,3% and chronic obstructive pulmonary disease 6,3%. Comparing bone mineral density before and after the first treatment of zoledronic acid infusion, the mean value of Tscore has improved but there is not statistically significant (femoral neck p=0.6096, lumbar spine p=0.3976). In terms of treatment, bone mineral density dose not decrease overtime, there is an improvement after treatment. The most common adverse reactions at the first treatment are fever 65,6%, myalgia 46,9%, pseudo-flu 34,4%, joint pain 9,4%. Compared with the first time, in the second treatment, there are no cases of muscle pain, pseudo-flu and joint pain but fever 34,4%. After treatment, walking, movement and joint pain are improved 100%. Conclusion: Zoledronic acid (Aclasta 5mg/100ml) effectively improves bone mineral density after one year and is safe in osteoporosis patients in both treaments.